Search Result

Results for "

prion diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Prion Protein (13) Adrenergic Receptor (1) Amyloid-β (2) Apoptosis (3) Bcr-Abl (3) Isotope-Labeled Compounds (1) JAK (3) Parasite (1) Reference Standards (1) STAT (3) Tau Protein (2) α-synuclein (1)
By Research Areas:	Cancer (3) Infection (11) Neurological Disease (14)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Prion Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101855

Emrusolmin Anle138b	Amyloid-β	Neurological Disease
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .

HY-15728

Radotinib 1 Publications Verification IY-5511	Bcr-Abl Apoptosis STAT JAK Prion Protein	Infection Neurological Disease Cancer
Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

HY-122066

NSC47924	Others	Infection
NSC47924 is a laminin receptor (LR) inhibitor. NSC47924 affects 37/67 kDa LR cell surface localization and interaction with the cellular prion protein. NSC47924 can be used for testing prion diseases .

HY-160831

PQQ-trimethylester 1 Publications Verification PQQ-TME	α-synuclein	Neurological Disease
PQQ-trimethylester (PQQ-TME) is a synthetic compound that is a trimethylester derivative of pyrroloquinoline quinone (PQQ). PQQ-trimethylester has twice the blood-brain barrier permeability of PQQ (HY-100196) in vitro. In addition, PQQ-trimethylester shows strong inhibitory activity against α-synuclein, amyloid β1-42 (Aβ1-42) and prion protein fibrillation. PQQ-trimethylester can be used in the study of neurodegenerative diseases .

HY-150286

SM875	Prion Protein	Neurological Disease
SM875 is a cellular prion protein (PrP) degrader (IC₅₀: 7.87 μM). SM875 targets PrP folding intermediates and promotes its degradation through the autophagy-lysosomal pathway. SM875 only acts on nascent, immature PrP molecules and has no effect on mature PrP before synthesis. SM875 can inhibit prion replication and has potential in the study of neurodegenerative diseases (i.e., prion diseases) .

HY-153427

Tau protein aggregation-IN-1	Tau Protein	Neurological Disease
Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies .

HY-177630

Erisonersen ION 717	Prion Protein	Infection
Erisonersen, an antisense oligonucleotide, is a prion protein synthesis reducer. It is used for the study of Prion disease.

HY-P990167

Anti-Mouse/Human PrP/prion protein Antibody (TW1)	Prion Protein Tau Protein	Neurological Disease
Anti-Mouse/Human PrP/prion protein Antibody (TW1) is a mouse-derived IgG2a type antibody inhibitor, targeting to mouse/human *PrP/prion* protein*. Anti-Mouse/Human PrP/prion* protein Antibody (TW1) binds to both PrPc (cellular prion protein) and PrPSc (Scrapie Prion Protein) and blocks the interaction of prion protein with tau protein. Anti-Mouse/Human PrP/prion protein Antibody (TW1) can be used for the researches of Alzheimer’s disease (AD) .

HY-P10534

ccβ	Prion Protein	Infection Neurological Disease
CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation .

HY-177630A

Erisonersen sodium ION 717 sodium	Prion Protein	Infection
Erisonersen sodium, an antisense oligonucleotide, is a prion protein synthesis reducer. It is used for the study of Prion disease.

HY-150286A

(R)-SM875	Prion Protein	Infection
(R)-SM875 is a degrader targeting the intermediate folding form of prion protein (PrP). (R)-SM875 significantly reduces the PrP level, with an IC₅₀ of 3 μM. (R)-SM875 can be used for the study of prion diseases .

HY-115360

IND45193	Prion Protein	Others
IND45193 is a compound used to inhibit prion disease, with activity in reducing PrP(Sc) levels. In cells infected with prions, IND45193 can reduce PrP(Sc) levels, and its activity was determined through screening of multiple cell types and concentration-effect relationship studies.

HY-15728S

Radotinib-d6 IY-5511-d₆	Isotope-Labeled Compounds Bcr-Abl Apoptosis STAT JAK Prion Protein	Infection Neurological Disease Cancer
Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

HY-124375

IND81	Prion Protein	Infection
IND81 is an orally active antiprion with IC₅₀ value of 1.95 μM. IND81 reduces abnormal, misfolded, disease-causing forms of benign prion proteins that are normally present on or within cells .

HY-175136

Chloroguanabenz acetate GAh acetate	Adrenergic Receptor	Infection Neurological Disease
Chloroguanabenz (acetate) is an antiprion agent and a derivative of the α₂-adrenergic receptor agonist guanabenz. Chloroguanabenz (acetate) can inhibit the formation of prion in yeast and mammalian in vitro assays. Chloroguanabenz (acetate) can reduce the levels of truncated Huntingtin derivative Htt48 in HEK293T cells. Chloroguanabenz (acetate) can be studied in research on Huntington’s disease .

HY-147702

BB 0305179	Prion Protein	Infection Neurological Disease
BB 0305179 (compound 59) is a potent anti-prion agent, with an IC₅₀ of 4.7 μM. BB 0305179 inhibits the toxicity of a specific PrP mutant carrying a deletion in the hydrophobic domain . BB 0305179 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147371

Quinoprazine	Parasite	Infection Neurological Disease
Quinoprazine is a potent inhibitor of Vaccinia virus DNA synthesis with an IC₅₀ value of 10 μM. Quinoprazine has antimalarial activity against Plasmodium berghei and also displays antiprion potency, significantly decreases PrP ^{S ^c} levels ^- .

HY-P991957

PRN100	Prion Protein	Neurological Disease
PRN100 is a fully humanized monoclonal antibody against cellular prion protein (PrPᶜ), belonging to the IgG_4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 is designed to prevent cellular prion protein from being recruited and converted into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the study of Creutzfeldt-Jakob disease.

HY-179460

Radotinib dihydrochloride IY-5511 dihydrochloride	Bcr-Abl Apoptosis STAT JAK Prion Protein	Neurological Disease Cancer
Radotinib (IY-5511) dihydrochloride is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib dihydrochloride has anti-prion and anti-tumor activities. Radotinib dihydrochloride can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib dihydrochloride can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

HY-101855R

Emrusolmin (Standard) Anle138b (Standard)	Reference Standards Amyloid-β	Neurological Disease
Emrusolmin (Standard) (Anle138b (Standard)) is the analytical standard of Emrusolmin (HY-101855). This product is intended for research and analytical applications. Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .

Cat. No.	Product Name	Target	Research Area

HY-P10534

ccβ	Prion Protein	Infection Neurological Disease
CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990167

Anti-Mouse/Human PrP/prion protein Antibody (TW1)	Prion Protein Tau Protein	Neurological Disease
Anti-Mouse/Human PrP/prion protein Antibody (TW1) is a mouse-derived IgG2a type antibody inhibitor, targeting to mouse/human *PrP/prion* protein*. Anti-Mouse/Human PrP/prion* protein Antibody (TW1) binds to both PrPc (cellular prion protein) and PrPSc (Scrapie Prion Protein) and blocks the interaction of prion protein with tau protein. Anti-Mouse/Human PrP/prion protein Antibody (TW1) can be used for the researches of Alzheimer’s disease (AD) .

HY-P991957

PRN100	Prion Protein	Neurological Disease
PRN100 is a fully humanized monoclonal antibody against cellular prion protein (PrPᶜ), belonging to the IgG_4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 is designed to prevent cellular prion protein from being recruited and converted into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the study of Creutzfeldt-Jakob disease.

Cat. No.	Product Name	Chemical Structure

HY-15728S

Radotinib-d6
Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

Radotinib-d6

Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

Cat. No.	Product Name		Classification

HY-177630

Erisonersen ION 717		Antisense Oligonucleotides
Erisonersen, an antisense oligonucleotide, is a prion protein synthesis reducer. It is used for the study of Prion disease.

HY-177630A

Erisonersen sodium ION 717 sodium		Antisense Oligonucleotides
Erisonersen sodium, an antisense oligonucleotide, is a prion protein synthesis reducer. It is used for the study of Prion disease.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.